In Response

Affiliations

¹ Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
² Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany; Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
³ Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. Electronic address: ahillmer@uni-koeln.de.

Free article

Comment

Cristoph Arolt et al. J Thorac Oncol. 2023 Nov.

Free article

. 2023 Nov;18(11):e128-e129.

doi: 10.1016/j.jtho.2023.08.025.

¹ Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
² Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany; Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
³ Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. Electronic address: ahillmer@uni-koeln.de.

No abstract available

Comment on

"Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
Niu Y, Yao F, Yang H. Niu Y, et al. J Thorac Oncol. 2023 Nov;18(11):e126-e128. doi: 10.1016/j.jtho.2023.08.001. J Thorac Oncol. 2023. PMID: 37879768 No abstract available.